ZIRCONIUM SILICATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	O4Si.Zr
Molecular Weight	183.307
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Zr+4].[O-][Si]([O-])([O-])[O-]

InChI

InChIKey=GFQYVLUOOAAOGM-UHFFFAOYSA-N

InChI=1S/O4Si.Zr/c1-5(2,3)4;/q-4;+4

HIDE SMILES / InChI

Molecular Formula	O4Si
Molecular Weight	92.0831
Charge	-4
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Zr
Molecular Weight	91.224
Charge	4
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25531770 | https://www.fda.gov/Drugs/InformationOnDrugs/ucm609666.htm

Zyrconium cyclosilicate (ZS-9) is a selective oral sorbent that traps potassium ions throughout the gastrointestinal tract. ZS-9 is not systemically absorbed; accordingly, the risk of systemic toxicity may be minimized. ZS-9 was originally developed by ZS Pharma, and later licensed to AstraZeneca. In 2018 the FDA has approved ZS-9 for treatment of hyperkalemia.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
potassium ion homeostasis 1 Target ID: GO:0055075 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25531770	Chelating Agent 142

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hyperkalemia 11 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207078s000lbl.pdf	Primary		Approved 8429	LOKELMA Approved Use Uses Multi-purpose mineral powder provides broad-spectrum SPF 46 PA+++ protection. Leaves the skin flawless and protected. Launch Date 2018

PubMed

Title	Date	PubMed
Characterization of structure and function of ZS-9, a K+ selective ion trap.	2014	25531770

Patents

Sample Use Guides

In Vivo Use Guide

For initial treatment of hyperkalemia, the recommended dose of Lokelma is 10 g administered three times a day for up to 48 hours as a suspension in water. For continued treatment, the recommended dose is 10 g once daily.

Route of Administration: Oral

In Vitro Use Guide

Equal concentrations (100–200 mg) of ZS-9 was added to 20 mL solutions containing standard ppm concentrations of K+, in addition to Ca2+ and Mg2+ at different ratios (1∶0.5∶0.5, 1∶1∶1, 1∶2∶2). After 2 hours of gentle agitation at room temperature, an aliquot was taken from the supernatant and the cations quantified by ion chromatography using a Dionex Model ICS-1100 (Thermo Scientific, USA), coupled to an AS-DV autosampler. The exchange capacity for K+ ions was 2.6-2.8 mEq/g.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 02:16:04 GMT 2023` Edited by `admin` on `Sat Dec 16 02:16:04 GMT 2023`
Record UNII	4SY8H89134
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZIRCONIUM SILICATE

Official Name

English

SILICON ZIRCONIUM OXIDE (SIZRO4)

Common Name

English

ZIRCONIUM(IV) SILICATE (1:1)

Systematic Name

English

ZIRCON FLOUR 100

Brand Name

English

SILICIC ACID (H4SIO4), ZIRCONIUM(4+) SALT (1:1)

Common Name

English

ZIRCONITE

Common Name

English

ZIRCONIUM SILICATE [INCI]

Common Name

English

ZIRCOSIL

Brand Name

English

ZIRCONIUM SILICATE [MI]

Common Name

English

SILICIC ACID, ZIRCONIUM SALT (1:1)

Common Name

English

ZIRCONIUM SILICON OXIDE

Common Name

English

MICRO-PAX

Brand Name

English

ZIRCON

Common Name

English

SILICON ZIRCONIUM OXIDE (ZRSIO4)

Common Name

English

ZIRCONIUM ORTHOSILICATE

Systematic Name

English

Zirconium silicate [WHO-DD]

Common Name

English

Code System Code Type Description

CAS

1344-21-4